Correlation Between RenovaCare and Scopus Biopharma
Can any of the company-specific risk be diversified away by investing in both RenovaCare and Scopus Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining RenovaCare and Scopus Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between RenovaCare and Scopus Biopharma, you can compare the effects of market volatilities on RenovaCare and Scopus Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in RenovaCare with a short position of Scopus Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of RenovaCare and Scopus Biopharma.
Diversification Opportunities for RenovaCare and Scopus Biopharma
0.0 | Correlation Coefficient |
Pay attention - limited upside
The 3 months correlation between RenovaCare and Scopus is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding RenovaCare and Scopus Biopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Scopus Biopharma and RenovaCare is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on RenovaCare are associated (or correlated) with Scopus Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Scopus Biopharma has no effect on the direction of RenovaCare i.e., RenovaCare and Scopus Biopharma go up and down completely randomly.
Pair Corralation between RenovaCare and Scopus Biopharma
If you would invest 3.00 in RenovaCare on September 3, 2024 and sell it today you would lose (2.99) from holding RenovaCare or give up 99.67% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Flat |
| Strength | Insignificant |
| Accuracy | 0.68% |
| Values | Daily Returns |
RenovaCare vs. Scopus Biopharma
Performance |
| Timeline |
| RenovaCare |
| Scopus Biopharma |
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
RenovaCare and Scopus Biopharma Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with RenovaCare and Scopus Biopharma
The main advantage of trading using opposite RenovaCare and Scopus Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if RenovaCare position performs unexpectedly, Scopus Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Scopus Biopharma will offset losses from the drop in Scopus Biopharma's long position.| RenovaCare vs. Pmv Pharmaceuticals | RenovaCare vs. MediciNova | RenovaCare vs. Pharvaris BV | RenovaCare vs. PepGen |
| Scopus Biopharma vs. Scpharmaceuticals | Scopus Biopharma vs. DiaMedica Therapeutics | Scopus Biopharma vs. Monopar Therapeutics | Scopus Biopharma vs. Pasithea Therapeutics Corp |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Other Complementary Tools
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |